Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma

Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma

BackgroundProteasome inhibitor Carfilzomib (CFZ) is effective in treating patients with refractory or relapsed multiple myeloma (MM) but has been associated with cardiovascular adverse events (CVAE) such as hypertension, cardiomyopathy, and heart failure. This study aimed to investigate the contribu...

Full description

Bibliographic Details
Main Authors: Marwa Tantawy, Guang Yang, Raghunandan Reddy Algubelli, Gabriel DeAvila, Samuel M. Rubinstein, Robert F. Cornell, Michael G. Fradley, Erin M. Siegel, Oliver A. Hampton, Ariosto S. Silva, Daniel Lenihan, Kenneth H. Shain, Rachid C. Baz, Yan Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardio-oncology
proteosome inhibitors
Multiple Myeloma
carfilzomib
cardiotoxcity
whole exome sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1181806/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1181806/full

Similar Items